Pfizer-BioNTech COVID-19 Shot Safe, Effective Through Six Months After Second Dose

Pfizer Inc PFE and BioNTech SE BNTX have announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in Phase 3 study through March 13.
Data showed that the vaccine, BNT162b2, was 91.3% effective against COVID-19 infection, measured seven days through up to six months after the second dose.
According to US CDC, the vaccine was 100% effective against severe disease and 95.3% effective against severe COVID-19 as defined by the FDA.
Safety data collected from more than 12,000 vaccinated participants who have a follow-up time of at least six months after the second dose demonstrated a favorable safety and tolerability profile.
The vaccine was 100% effective in preventing COVID-19 cases in South Africa, where the B.1.351 lineage is prevalent.
No serious safety concerns were observed in trial participants up to six months after the second dose. Side effects were generally consistent with previously reported results.
The companies plan to submit detailed data for scientific peer review and potential publication soon.
Yesterday, Pfizer-BioNTech announced compelling data that showed 100% efficacy against the infection in adolescents aged between 12 to 15 years.
Price Action: PFE shares are up 0.22% at $36.31, and BNTX shares moved 1.1% higher at $110.4 in the premarket trading on the last check Thursday.